Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290322 | 0.77 | KIF11 (0.33) | RIPK1 | |
| SCHEMBL17433678 | 0.73 | CA2 (0.37) | RIPK1CA2MAPK1CHRM1AKR1A1 | |
| SCHEMBL4053641 | 0.73 | TP53 (0.33) | RIPK1CA2MAPK1CHRM1AKR1A1 | |
| SCHEMBL4954102 | 0.72 | — | — | |
| SCHEMBL1666550 | 0.72 | RNPEP (0.46) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL23383641 | 0.70 | RIPK1 (0.31) | RIPK1CA2MAPK1CHRM1AKR1A1 | |
| SCHEMBL474110 | 0.70 | ENPEP (0.35) | RIPK1 | |
| SCHEMBL14341529 | 0.69 | TSHR (0.33) | RIPK1TDP1 | |
| SCHEMBL8463336 | 0.69 | RIPK1 (0.32) | RIPK1CA2TDP1 | |
| SCHEMBL10044964 | 0.69 | CYP1A2 (0.38) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218407-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-07-04 | — | — | US | disclosed |
| US-11926857-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20210277432-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-09-09 | — | — | US | disclosed |
| US-11046982-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200157588-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10590445-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180187225-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2018-07-05 | — | — | US | disclosed |
| US-9932616-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170081685-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-03-23 | — | — | US | disclosed |
| US-9546388-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| CN-102574896-B | variant LovD polypeptides and uses thereof | CODEXIS INC | 2015-04-08 | — | — | CN | disclosed |
| US-20150037851-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-02-05 | — | — | US | disclosed |
| EP-2483292-B1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | CODEXIS INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8846362-B2 | Variant LOVD polypeptides and their uses | CODEXIS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130130351-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | CODEXIS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383382-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2483292-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | Codexis, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| CN-102574896-A | Variant LovD polypeptides and uses thereof | CODEXIS INC | 2012-07-11 | — | — | CN | disclosed |
| US-20110111468-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | CODEXIS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011041231-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | CODEXIS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590445-B2 | Variant LovD polypeptides and their uses | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
| US-11046982-B2 | Variant LovD polypeptides and their uses | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
| US-20210277432-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
| US-11926857-B2 | Variant LovD polypeptides and their uses | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
| US-20200157588-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
| US-20180187225-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
| US-20110111468-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | PCSK9, HMGCR, LCAT | RIPK1 2960/4885CA2 4562/4885MAPK1 4420/4885 |
| US-20240218407-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | RIPK1 3214/4885CA2 4518/4885MAPK1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.